Ignyta to Participate at the Global Mizuho Investor Conference

Ignyta, Inc. RXDX, a biotechnology company focused on precision medicine in oncology, announced today that it will participate in investor meetings at the Global Mizuho Investor Conference on December 5, 2017, in New York City.

Investors who wish to meet with the Company's management during this conference should contact the conference coordinator.

About Ignyta, Inc.

Blazing a New Future for Patients with Cancer™

At Ignyta, we work tirelessly on behalf of patients with cancer to offer potentially life-saving, precisely targeted therapeutics (Rx) guided by diagnostic (Dx) tests. Our integrated Rx/Dx strategy allows us to enter uncharted territory, illuminating the molecular and immunological drivers of cancer and quickly advancing treatments to address them. This approach embraces even those patients with rare cancers, who have the highest unmet need and who may otherwise not have access to effective treatment options. With our pipeline of potentially first-in-class or best-in-class precision medicines, we are pursuing the ultimate goal of not just shrinking tumors, but eradicating cancer relapse and recurrence in precisely defined patient populations.

For more information, please visit: www.ignyta.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171129005401/en/